End-to-end services for Cell&Gene therapies
Cell and gene therapies represent a promising new approach to treating a wide range of diseases. Various settings are possible in these therapies, that can include the use of cells or gene edited cells (either ex-vivo or in-vivo).
Eurofins CDMO offers a comprehensive suite of end-to-end services for cell and gene therapy development and manufacturing, supporting companies through the entire process from preclinical stages to commercialization.
Our commitment to science and quality ensures that we provide sustainable and flexible solutions tailored to your specific project requirements. Of note, process development and manufacturing services are completed by unparalleled in-house QC capacity leveraging our expertise and global network of facilities, and offering both analytical platform methods and custom product-specific assays.
Molecular Therapies
- Plasmid DNA (pDNA) manufacturing from R&D to full GMP grade
- Recombinant protein (e.g. nucleases) process development and manufacturing from R&D to full GMP grade
- Development and Manufacturing of Lipid Nano Particles (LNP) formulations
- Establishment of Master Cell Banks (MCB) and Working Cell Banks (WCB)
Cell&Gene Therapies
- Process development and optimization of adherent (e.g. MSC) and suspension (e.g. CD34+, T cells, and NK) cells
- Gene Editing with Viral and Non-Viral manufacturing platforms
Viral Vectors
-
Packaging plasmids (LVV)
-
Process development and optimization for viral vectors
We can accompany you from discovery to market
Eurofins network of companies supports Cell and Gene Therapies from Discovery to Commercialisation taking advantage of the expertise of its dedicated divisions
Discover Eurofins synergy
We are dedicated to helping you bring your innovative Cell & Gene therapies to market